Cosentyx® (secukinumab) – New indication
June 17, 2020 - Novartis announced the FDA approval of Cosentyx (secukinumab), for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.
Download PDF
